TRACON Pharmaceuticals, Inc.
TCON · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $3 | $20 | $9 | $7 |
| - Cash | $6 | $8 | $9 | $8 |
| + Debt | $0 | $0 | $1 | $1 |
| Enterprise Value | -$3 | $12 | $1 | -$0 |
| Revenue | $0 | $0 | $3 | $0 |
| % Growth | -45% | -96.7% | – | – |
| Gross Profit | $0 | $0 | $3 | -$0 |
| % Margin | 100% | 96% | 99.9% | – |
| EBITDA | -$3 | -$3 | $0 | $11 |
| % Margin | -5,287.3% | -3,208% | 13.3% | – |
| Net Income | -$3 | -$3 | $0 | $11 |
| % Margin | -5,161.8% | -3,168% | 14.4% | – |
| EPS Diluted | -0.94 | -1.33 | 0.18 | 5.8 |
| % Growth | 29.3% | -838.9% | -96.9% | – |
| Operating Cash Flow | -$3 | -$3 | -$1 | $15 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | -$3 | -$1 | $15 |